Description: Riviciclib sodium (P276-00) is a flavonoid analog which acts as a novel inhibitor of CDK1 (cyclin-dependent kinase), CDK4 and CDK9 with IC50 of 79 nM, 63 nM and 20 nM, respectively. P276-00 has the ability of arresting the cells in G1/S phase transcription. When tested with NSCLC cell lines, P276-00 showed high ability of inhibiting cell proliferate thus decreased the colony forming potential via blocking cell cycle. In head and neck squamous carcinoma cell line (FaDu, Detroits-562, SCC-25), treated with P276-00 for 12 hours could significantly inhibit cell ability with IC50 value ranging from 0.8 to 1.7 uM for different cell lines via decreasing the expression of CCND1.

References: Mol Cancer Ther. 2007 Mar;6(3):918-25; Mol Cancer Ther. 2007 Mar;6(3):926-34.

Related CAS #: 920113-03-7 (HCl) 920113-02-6 (free base)

纯度：≥98%